Influenza virus RNA (vRNA)

Influenza virus RNA comprises the segmented, negative-sense single-stranded genome (vRNA) of the influenza virus, typically organized into eight distinct segments in types A and B (Dou et al., 2018, Nature Communications). Each segment is encapsulated by nucleoproteins and associated with a heterotrimeric RNA-dependent RNA polymerase complex, forming viral ribonucleoproteins (vRNPs) that serve as the templates for both transcription into messenger RNA and replication into complementary RNA (cRNA) (NIH, 2023). As the fundamental blueprint for viral protein synthesis and progeny production, this RNA is a critical target for antiviral therapy. Therapeutic strategies include the use of nucleoside analogues like Favipiravir, which induce lethal mutagenesis or chain termination upon incorporation into the viral genome (PubChem). Furthermore, the highly conserved regions of the RNA segments are targets for emerging gene-silencing technologies, such as siRNA and antisense oligonucleotides, which aim to disrupt viral replication by degrading the viral genetic material (Ge et al., 2003, PNAS). Understanding the structural constraints and evolutionary dynamics of influenza RNA is essential for developing treatments that can withstand the virus's high mutation rate and potential for reassortment.

Other names

vRNAViral RNAInfluenza genomic RNANegative-sense single-stranded RNA (ssRNA)

Inhibition of viral RNA-dependent RNA polymerase through nucleoside analog incorporation, resulting in lethal mutagenesis or chain termination; sequence-specific degradation via RNA interference (siRNA) or antisense oligonucleotides (Furuta et al., 2013, Antiviral Research; Ge et al., 2003, PNAS).